News from alkermes plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

12 Jun, 2019, 12:00 BST Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the monotherapy expansion stage of its ARTISTRY-1 clinical trial to evaluate the...


22 May, 2019, 12:00 BST Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its mental health portfolio at the American Society of Clinical...


14 May, 2019, 21:01 BST Alkermes to Present at the UBS Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson, will participate in a fireside chat...


13 May, 2019, 12:00 BST Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences

Alkermes plc (Nasdaq: ALKS) today announced that it will present data from its mental health portfolio at the American Psychiatric Association (APA)...


25 Apr, 2019, 12:00 BST Alkermes Plc Reports First Quarter 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2019. "Our first quarter results reflect the diversity of our...


24 Apr, 2019, 21:01 BST Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

Alkermes plc (Nasdaq: ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the...


18 Apr, 2019, 21:00 BST Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Apr. 25, 2019, to...


09 Apr, 2019, 12:00 BST Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

-- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month...


08 Apr, 2019, 22:15 BST Alkermes Announces Departure of Jim Robinson

Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave...


03 Apr, 2019, 12:00 BST Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, an initiative designed to support...


01 Apr, 2019, 12:00 BST Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

Alkermes plc (Nasdaq: ALKS) today announced it will present new data related to its schizophrenia disease portfolio at the 2019 Congress of the...


05 Mar, 2019, 21:01 GMT Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39th Annual Health Care...


26 Feb, 2019, 12:00 GMT Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as...


25 Feb, 2019, 12:30 GMT Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...


20 Feb, 2019, 21:01 GMT Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink...


19 Feb, 2019, 12:00 GMT Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies

Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies have entered into a research collaboration to ...


07 Feb, 2019, 21:01 GMT Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Feb. 14, 2019, to...


01 Feb, 2019, 21:01 GMT Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...


16 Jan, 2019, 12:00 GMT Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

Alkermes plc (Nasdaq: ALKS) today announced the recipients of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, designed to support the next...


02 Jan, 2019, 21:00 GMT Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 37th Annual J.P. Morgan Healthcare Conference ...


17 Dec, 2018, 12:30 GMT Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food...


29 Nov, 2018, 12:01 GMT Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), ...


06 Nov, 2018, 21:01 GMT Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27th Annual Healthcare...


06 Nov, 2018, 13:01 GMT Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual...